Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Study of Blinatumomab Safety and Effectiveness, Utilization, and Treatment Practices

Trial Profile

An Observational Study of Blinatumomab Safety and Effectiveness, Utilization, and Treatment Practices

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Jan 2019

At a glance

  • Drugs Blinatumomab (Primary)
  • Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 31 Jul 2018 Planned End Date changed from 18 Mar 2022 to 22 Feb 2022.
    • 31 Jul 2018 Planned primary completion date changed from 18 Mar 2022 to 22 Feb 2022.
    • 04 Jul 2018 Planned End Date changed from 22 Feb 2022 to 18 Mar 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top